BioCorRx (BICX) Notes Payables (2013 - 2026)

BioCorRx has reported Notes Payables for 15 years, with the latest figure at $1.2 million in Q1 2026.

• Quarterly Notes Payables fell 16.83% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 16.83% YoY) and the FY2025 annual result came in at $1.2 million, down 8.97% from the prior year.
• Notes Payables grew to $1.2 million in Q1 2026 per BICX's latest filing, from $1.2 million in the prior quarter.
• Over five years, Notes Payables peaked at $1.5 million in Q3 2025 and troughed at $221480.0 in Q1 2022.
• A 5-year average of $905720.7 and a median of $1.0 million in 2024 frame the typical range for Notes Payables.
• The widest YoY moves for Notes Payables: up 931.1% in 2022, down 62.33% in 2022.
• Over 5 years, Notes Payables stood at $297602.0 in 2022, then jumped by 103.88% to $606750.0 in 2023, then jumped by 121.39% to $1.3 million in 2024, then fell by 8.97% to $1.2 million in 2025, then gained by 1.37% to $1.2 million in 2026.
• According to Business Quant data, Notes Payables over the past three periods registered $1.2 million, $1.2 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.